High grade serous carcinoma accounts for the majority of ovarian cancer mortality due to its aggressive behavior and late-stage diagnosis. Despite advances in surgery and chemotherapy over the past three decades, survival rates have stagnated, largely because the tumor develops sophisticated mechanisms to bypass immune surveillance. Among these mechanisms, the formation of multicellular spheroids within the peritoneal cavity stands out — these dense clusters of cancer cells are chemoresistant and facilitate metastasis within the abdominal cavity. Yet, the molecular factors that promote spheroid resilience against immune cell attack have remained obscure until now.

Podocalyxin, a highly glycosylated sialomucin related to CD34, has previously been linked to poor outcomes in HGSC patients. It is expressed abundantly on the surface of aggressive tumor cells and is known to contribute to tumor cell adhesion, migration, and chemoresistance. The current study sought to investigate whether PODXL also mediates immune evasion by protecting cancer spheroids from destruction by NK cells, which are innate immune effectors capable of identifying and killing transformed or infected cells without prior sensitization.

To explore this, researchers utilized an in vitro co-culture system where spheroids derived from Kuramochi cells — an HGSC cell line exhibiting the highest endogenous levels of PODXL among tested lines — were grown in the presence of primary human NK cells isolated from peripheral blood mononuclear cells (PBMCs). They compared the infiltration and cytotoxic effects in spheroids formed by wild-type cells versus those engineered to lack PODXL through gene knockout techniques. This innovative experimental design allowed a direct assessment of PODXL’s role in modulating immune interactions within a physiologically relevant 3D cancer model.

Over a time course of 24, 48, and 72 hours, data showed that spheroids deficient in PODXL were significantly more susceptible to NK cell penetration and subsequent killing. In contrast, PODXL-expressing spheroids remained compact and largely impervious to NK cell infiltration, exhibiting higher proliferation rates despite immune challenge. These findings demonstrate that PODXL confers a physical and biochemical barrier to NK cells, effectively sanctifying the tumor spheroids from immune-mediated destruction.

Further validation came from studies with primary malignant spheroids isolated from the ascitic fluid of HGSC patients, which mirrored the cell line results. Spheroids with lower levels of PODXL showed increased NK cell infiltration and cytolysis, whereas those with high PODXL expression resisted immune attack. This translational aspect underscored the clinical relevance of PODXL as a marker of spheroid robustness and immune escape in the ovarian cancer microenvironment.

On a mechanistic level, PODXL’s dense sialylated glycocalyx likely impedes NK cell recognition and adhesion by masking activating ligands or by engaging inhibitory receptors on NK cells. Additionally, the compactness of PODXL-rich spheroids physically restricts immune cell penetration. This dual role positions PODXL as a master regulator of both molecular and structural defenses against innate immune effectors, enabling spheroid persistence in the hostile immune milieu of the peritoneal cavity.

The implications of these findings are vast. Targeting PODXL or its downstream pathways could disrupt spheroid integrity and enhance NK cell-mediated clearance, augmenting current immunotherapeutic approaches that have so far had limited success in ovarian cancer. Therapeutic antibodies, small molecules, or genetic strategies aimed at PODXL might restore immune surveillance and sensitize tumors to chemotherapy by dismantling these resistant spheroid architectures.

Moreover, this discovery sheds light on the broader phenomenon of tumor immune evasion not merely through adaptive immune suppression but via physical barriers erected by tumor cells themselves. In the context of HGSC, where metastatic spread within the peritoneum relies heavily on spheroid formation, elucidating the role of PODXL opens new avenues for research into the tumor microenvironment, metastatic processes, and host-tumor immune interactions.

Ongoing and future studies will be critical to decipher the full spectrum of PODXL’s interactions with immune cells and the molecular signaling networks involved. In particular, exploring how PODXL expression is regulated in response to microenvironmental cues and therapy resistance will provide further insights into its role as an oncogenic facilitator and immune modulator.

This research represents a significant leap forward in understanding the cellular armor that cancer employs to evade innate immunity. As NK cells are central to the first line of defense against malignancies, unraveling mechanisms such as PODXL-mediated protection is key to harnessing their full therapeutic potential. The findings by Tran et al. offer hope that strategies disrupting this protective barrier can improve outcomes for patients afflicted with high grade serous ovarian cancer — a disease that desperately needs innovative interventions.

In summary, the study reveals a novel immune evasion mechanism in HGSC whereby podocalyxin expression in tumor spheroids curtails NK cell infiltration and cytotoxicity. These data not only clarify a long-standing question regarding spheroid resilience but also identify PODXL as a promising target for therapeutic development. With the potential to enhance immune-mediated tumor clearance, these insights mark an exciting frontier in ovarian cancer biology and treatment innovation.

The dynamic interplay between tumor cells and immune cells continues to be a fertile ground for discovery, and podocalyxin’s role adds a new dimension to this complex relationship. As the field progresses, integrating such molecular insights with clinical practice could revolutionize the management of aggressive cancers characterized by immune escape and treatment resistance.

Tran and colleagues’ meticulous work underscores the necessity of multidisciplinary approaches combining cellular biology, immunology, and clinical oncology to confront the challenges posed by metastatic ovarian cancer. Their findings provide a foundation for future translational studies aimed at disrupting tumor defenses and reinvigorating the innate immune system’s capacity to combat cancer.

Subject of Research: High grade serous ovarian cancer and the role of podocalyxin in mediating immune evasion from NK cell infiltration.

Article Title: Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction.

Article References:
Tran, N.L., Wang, Y., Quinn, K.M. et al. Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction. BMC Cancer 25, 1674 (2025). https://doi.org/10.1186/s12885-025-15108-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15108-6

Keywords: High grade serous carcinoma, podocalyxin, ovarian cancer, spheroids, immune evasion, natural killer cells, NK cell cytotoxicity, tumor microenvironment, cancer spheroids, chemoresistance, immune infiltration, tumor immune escape, peritoneal metastasis, glycoproteins, innate immunity

The study delves into the mechanisms behind cisplatin resistance, a common obstacle faced during ovarian cancer treatments. Cisplatin works by damaging the DNA of cancer cells, thereby inhibiting their ability to proliferate. However, many patients experience a remarkable decline in the effectiveness of this drug over time, as cancer cells develop resistance through various biological pathways. The ability of certain cancer cells to repair DNA damage efficiently is a key factor in their survival, necessitating innovative strategies to mitigate these resistant traits.

Astragalus Membranaceus, a traditional herb used in Chinese medicine, emerges as a compelling candidate for augmenting the effects of cisplatin. Historically, it has been credited with various health benefits, including immune enhancement and anti-inflammatory properties. Recent research suggests that the bioactive compounds found within Astragalus Membranaceus may play an instrumental role in modulating cancer cell responses to chemotherapy. By potentially downregulating DNA repair mechanisms in cancer cells, this herb may restore the sensitivity of these cells to cisplatin treatment.

Utilizing network pharmacology, the researchers mapped the interactions between the active components of Astragalus Membranaceus and key biological targets involved in the pathways of cisplatin resistance. This comprehensive analysis not only illuminates the pharmacological action of the herb but also identifies potential molecular targets that could be leveraged to enhance the overall effectiveness of chemotherapy. The results of their network pharmacology analysis provide a robust foundation for further empirical investigation into the combinatory regimen.

The experimental validation phase of the study involved a series of preclinical trials to evaluate the synergistic effects of combining Astragalus Membranaceus with cisplatin in ovarian cancer models. The outcomes were promising, showing a significant reduction in cell viability and increased apoptosis rates in cancer cells treated with the combination therapy compared to those treated with cisplatin alone. This evidence supports the hypothesis that Astragalus Membranaceus might indeed be a critical adjunct in combating cisplatin resistance.

In the course of the study, the researchers also observed alterations in the expression of specific genes associated with drug resistance mechanisms. The combination therapy led to downregulation of these genes, which are typically overexpressed in resistant ovarian cancer cell lines. This molecular insight underscores the potential role of Astragalus Membranaceus in altering cellular signaling pathways that promote drug resistance, thus paving the way for improved therapeutic outcomes.

Moreover, patient-centric approaches are steadily gaining traction in the field of oncology. This study aligns with that trend by emphasizing personalized medicine. The interactions and variations in patient response to both cisplatin and herbal treatments can heavily influence treatment efficacy. Future investigations may focus on tailoring these combined therapies based on genetic profiles, potentially allowing for more personalized treatment strategies for ovarian cancer patients facing cisplatin resistance.

In addition to providing clinical benefits, combining Astragalus Membranaceus with mainstream chemotherapy could also enhance the overall quality of life for patients. Since the herbal supplement is generally well-tolerated and has a favorable side effect profile, integrating it into treatment regimens may minimize harsh side effects often associated with high-dose chemotherapy. This highlights the broader implications of pharmacological synergies, which not only strive for increased efficacy but also improved patient well-being.

The study’s implications resonate beyond ovarian cancer. As resistance mechanisms are not confined to cisplatin alone, exploring other herbal combinations may lead to a broader spectrum of synergistic therapies applicable across various cancers. This could usher in a new era of treatment modalities that incorporate traditional knowledge with modern pharmacology, responding more effectively to the inherent challenges posed by drug-resistance.

The pursuit of innovative cancer therapies such as this study represents a shift in the narrative surrounding cancer treatment. Emphasizing the collaboration between traditional medicine and modern science may unlock new pathways to tackle complicated conditions like ovarian cancer. As researchers continue to probe the depths of this intersection, we may soon witness a transformative shift in how we approach cancer treatment strategies, particularly in resistant cases.

In conclusion, the collaborative research led by Wang, F. et al. demonstrates that integrating Astragalus Membranaceus with conventional chemotherapy presents a promising strategy to address the significant challenge of cisplatin resistance in ovarian cancer. This novel treatment approach not only provides a glimmer of hope for improved patient outcomes but also lays the groundwork for further research into the multi-faceted role of herbal medicine in oncological therapies. The feasibility of such interventions encourages the exploration of synergistic treatments as a viable route for those affected by cancer.

The hope is that ongoing inquiries into this combination therapy will elucidate even more complex interactions and mechanisms. As knowledge in this field expands, the legacy of traditional medicinal practices might find a strengthened footing within Western medical paradigms, potentially reshaping treatment methodologies in ways we are just beginning to comprehend.

Subject of Research: The study investigates the combined use of Astragalus Membranaceus and cisplatin in overcoming cisplatin resistance in ovarian cancer.

Article Title: Synergistic overcoming of cisplatin resistance in ovarian cancer by combined Astragalus Membranaceus and cisplatin treatment: network pharmacology and experimental validation.

Article References:

Wang, F., Yue, Qf., Zhang, Y. et al. Synergistic overcoming of cisplatin resistance in ovarian cancer by combined Astragalus Membranaceus and cisplatin treatment: network pharmacology and experimental validation.
BMC Complement Med Ther 25, 337 (2025). https://doi.org/10.1186/s12906-025-05066-8

Image Credits: AI Generated

DOI: 10.1186/s12906-025-05066-8

Keywords: Cisplatin resistance, Ovarian cancer, Astragalus Membranaceus, Network pharmacology, Synergistic treatment